Medochemie Limited Sustainability Profile
Medochemie Limited, headquartered in Cyprus, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and marketing of high-quality generic and branded medications. Founded in 1976, the company has established a strong presence across Europe, Asia, and Africa, with a commitment to enhancing global health through accessible healthcare solutions. With a diverse portfolio that includes a wide range of therapeutic areas, Medochemie is recognised for its innovative approach to drug formulation and delivery. The company’s core products encompass both prescription and over-the-counter medications, distinguished by their rigorous quality standards and affordability. Medochemie's dedication to research and development has positioned it as a trusted partner in the healthcare sector, contributing to its reputation as a leader in the pharmaceutical market.
DitchCarbon Score
How does Medochemie Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medochemie Limited's score of 17 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medochemie Limited's reported carbon emissions
Medochemie Limited, headquartered in Cyprus (CY), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Medochemie may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As a result, the company does not appear to be actively participating in industry-standard climate frameworks such as the Science Based Targets initiative (SBTi) or similar programmes.
How Carbon Intensive is Medochemie Limited's Industry?
How Carbon Intensive is Medochemie Limited's Location?
Medochemie Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medochemie Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
